Sotera Health (SHC) to Release Quarterly Earnings on Monday

Sotera Health (NASDAQ:SHC) will likely be announcing its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of $0.17 per share and revenue of $275.81 million for the quarter. Sotera Health has set its FY 2025 guidance at 0.700-0.760 EPS.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Thursday, May 1st. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. The business had revenue of $254.52 million for the quarter, compared to analysts’ expectations of $245.56 million. Sotera Health had a net margin of 2.24% and a return on equity of 41.08%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 EPS. On average, analysts expect Sotera Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sotera Health Stock Performance

Shares of Sotera Health stock opened at $12.30 on Monday. The firm’s fifty day simple moving average is $11.76 and its 200-day simple moving average is $12.11. The stock has a market capitalization of $3.49 billion, a price-to-earnings ratio of 153.77 and a beta of 1.81. Sotera Health has a 12 month low of $9.53 and a 12 month high of $17.08. The company has a debt-to-equity ratio of 5.55, a current ratio of 2.46 and a quick ratio of 2.19.

Analyst Upgrades and Downgrades

SHC has been the topic of a number of recent research reports. Barclays cut their target price on shares of Sotera Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, June 24th. Piper Sandler cut their target price on shares of Sotera Health from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, April 23rd. The Goldman Sachs Group raised shares of Sotera Health from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Finally, Wall Street Zen raised shares of Sotera Health from a “hold” rating to a “buy” rating in a research note on Saturday, June 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Hedge Funds Weigh In On Sotera Health

Several institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC boosted its position in shares of Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after purchasing an additional 14,018 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Sotera Health by 11.1% during the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock worth $332,000 after purchasing an additional 2,845 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Sotera Health by 14.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after purchasing an additional 43,471 shares in the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.